We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+21.94%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$53.3M
Cap. Flow
+$23M
Cap. Flow %
4.23%
Top 10 Hldgs %
49.87%
Holding
88
New
19
Increased
18
Reduced
25
Closed
23

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$13M
2
SRRK icon
Scholar Rock
SRRK
+$10.7M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$10.4M
4
PCVX icon
Vaxcyte
PCVX
+$9.43M
5
PFE icon
Pfizer
PFE
+$8.03M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$14.9M
2
VRNA
Verona Pharma
VRNA
+$13.9M
3
IRON icon
Disc Medicine
IRON
+$11.7M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$9.97M
5
WVE icon
Wave Life Sciences
WVE
+$8.49M

Sector Composition

Rank Sector Weight
1 Healthcare 90.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAPR icon
51
PUT
Capricor Therapeutics
CAPR
$380M
$1.44M 0.27%
+144,700
New +$1.53M
DCTH icon
52
Delcath Systems
DCTH
$399M
$1.4M 0.26%
103,026
-88,444
-46% -$1.23M
AKRO
53
CALL
DELISTED
Akero Therapeutics
AKRO
$1.33M 0.25%
25,000
-155,600
-86% -$7.07M
MRSN
54
DELISTED
Mersana Therapeutics
MRSN
$926K 0.17%
125,137
+1,597
+1% +$14K
RADX
55
Radiopharm Theranostics
RADX
$26.1M
$870K 0.16%
187,406
– –
MODD icon
56
Modular Medical
MODD
$12.7M
$529K 0.1%
23,679
-8,284
-26% -$221K
SNDX icon
57
CALL
Syndax Pharmaceuticals
SNDX
$1.74B
$468K 0.09%
+50,000
New +$550K
PRAX icon
58
Praxis Precision Medicines
PRAX
$8.25B
$421K 0.08%
10,000
-156,074
-94% -$5.94M
GUTS icon
59
Fractyl Health
GUTS
$115M
$328K 0.06%
202,590
-34,858
-15% -$56.3K
BDSX icon
60
Biodesix
BDSX
$218M
$302K 0.06%
53,518
-151,402
-74% -$1.22M
SGMT icon
61
Sagimet Biosciences
SGMT
$449M
$286K 0.05%
+37,539
New +$158K
ELVN icon
62
Enliven Therapeutics
ELVN
$3.84B
$201K 0.04%
+10,000
New +$189K
CNTA
63
DELISTED
Centessa Pharmaceuticals
CNTA
$65.7K 0.01%
5,000
-227,758
-98% -$2.89M
NKTR icon
64
Nektar Therapeutics
NKTR
$2.39B
$8.94K ﹤0.01%
+346
New +$3.88K
RCKTW icon
65
Rocket Pharmaceuticals Warrant
RCKTW
$352K
$3.02K ﹤0.01%
104,828
– –
ABVX
66
Abivax
ABVX
$10.8B
– –
-210,901
Closed -$1.32M
ALKS icon
67
Alkermes
ALKS
$8.47B
– –
-124,871
Closed -$4.12M
AVDL
68
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-39,366
Closed -$308K
BBIO icon
69
BridgeBio Pharma
BBIO
$16.8B
– –
-111,000
Closed -$3.84M
BPMC
70
DELISTED
Blueprint Medicines
BPMC
– –
-37,345
Closed -$3.31M
CCCC icon
71
C4 Therapeutics
CCCC
$393M
– –
-882,300
Closed -$1.41M
GILD icon
72
Gilead Sciences
GILD
$167B
– –
-62,029
Closed -$6.95M
IFRX icon
73
InflaRx
IFRX
$249M
– –
-1,161,567
Closed -$1.18M
IRON icon
74
Disc Medicine
IRON
$2.85B
– –
-236,471
Closed -$11.7M
KALA icon
75
KALA BIO
KALA
$12.3M
– –
-4,922
Closed -$1.41M
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Silverarc Capital Management held 88 positions worth $542M, up 11% from $489M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Silverarc Capital Management deployed $23M of net new capital in Q2 2025, opening 19 new positions and adding to 18 existing holdings. Its largest new stake was CG Oncology: 541,034 shares worth $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Nuvalent, an estimated $14.9M trimmed.

  • Silverarc Capital Management's largest Q2 2025 buy was CG Oncology: 541,034 shares worth $14.1M.
  • Silverarc Capital Management added most to Neurocrine Biosciences in Q2 2025, an estimated $10.4M increase.
  • Silverarc Capital Management's biggest Q2 2025 reduction was Nuvalent, cutting an estimated $14.9M.
  • Silverarc Capital Management fully exited Disc Medicine in Q2 2025, selling an estimated $11.7M.
  • Silverarc Capital Management's ten largest holdings make up 50% of its $542M portfolio in Q2 2025.
  • Silverarc Capital Management opened 19 new positions and closed 23 in Q2 2025.
  • Silverarc Capital Management's portfolio value rose 11% quarter-over-quarter to $542M.

Based on Silverarc Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.